The future of clinical research: networked, inclusive, engaging

The future of clinical research: networked, inclusive, engaging

As the societal transformation imposed by COVID-19 starts to become considered normal, daily life has changed and businesses in many sectors are adapting. The paradigm shift has been perhaps most profound in healthcare, where staff in primary, secondary and tertiary...
MedCannID insights from 1000 UK medical cannabis prescriptions

MedCannID insights from 1000 UK medical cannabis prescriptions

The number of patients in the UK exploring the option of medical cannabis on prescription continues to grow. Current estimates suggest that perhaps 6000 patients have been prescribed medical cannabis for a range of conditions in the UK, up from about 2000 at the turn...
Addressing ESG issues in the medicinal cannabis industry

Addressing ESG issues in the medicinal cannabis industry

As part of research at the University of Cambridge Institute for Sustainability Leadership, we developed and sent out a survey to a hundred key stakeholders in the global medicinal cannabis industry. Participating stakeholders were chosen from our network due to their...
ACMD assess impact of rescheduling. What can we learn?

ACMD assess impact of rescheduling. What can we learn?

Two years after the Advisory Council on the Misuse of Drugs (ACMD) recommended that Cannabis Based Products for Medicinal use (CBPM) be moved into Schedule 2 under the Misuse of Drugs Regulations 2001 (MDR), the ACMD reflect and assess the impact of this important...
Addressing ESG issues in the medicinal cannabis industry

Sustainability & Alta Flora

An intro to sustainability at Alta Flora Sustainability means different things to different people; it is a concept with a wide range of interpretations that are often easily confused. Should you want to familiarise yourself, our friend André Gonçalves at Youmatter...